Search results
Results From The WOW.Com Content Network
3-Methoxyamphetamine (3-MA), also known as meta-methoxyamphetamine (MMA), is a monoamine releasing agent (MRA) of the amphetamine family. [ 2 ] [ 3 ] [ 4 ] It is a positional isomer of para -methoxyamphetamine (PMA; 4-methoxyamphetamine).
3-Methoxymethamphetamine (also known as meta-methoxymethamphetamine or MMMA), which is most closely related to 3-methoxyamphetamine and PMMA and shares similar monoamine releasing effects, although its effects have not been studied so extensively as other related drugs.
Methoxyamphetamine may refer to: 2-Methoxyamphetamine (2-MA) or ortho -methoxyamphetamine (OMA) 3-Methoxyamphetamine (3-MA) or meta -methoxyamphetamine (MMA)
3,4-Methylenedioxy-N-methoxyamphetamine (MDMEO, MDMEOA, or MDMeOA) is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-methoxy analogue of MDA . MDMEO was first synthesized by Alexander Shulgin .
4-Hydroxy-3-methoxyamphetamine (HMA), also known as 3-O-methyl-α-methyldopamine, is an active metabolite of 3,4-methylenedioxymethamphetamine (MDMA). [ 1 ] [ 2 ] [ 3 ] It is substantially less potent than MDMA or 3,4-methylenedioxyamphetamine (MDA) as a monoamine releasing agent in vitro .
3,4-Methylenedioxyamphetamine (MDA) is an empathogen-entactogen, stimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. [3] In its pharmacology , MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA).
Methoxyphenamine was first synthesized at the Upjohn company by Woodruff and co-workers. [3] A later synthesis by Heinzelman, from the same company, corrects the melting point given for methoxyphenamine hydrochloride in the earlier paper, and describes an improved synthetic procedure, as well as resolution of the racemic methoxyphenamine.
Methamphetamine [note 1] (contracted from N-methylamphetamine) is a potent central nervous system (CNS) stimulant that is mainly used as a recreational or performance-enhancing drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder (ADHD). [24]